登录新浪财经APP 搜索【信披】查看更多考评等级 (三)关于议案表决的有关情况说明 上述议案中均为普通决议事项，经出席会议股东或股东代表所持有效表决权股份总数的1/2以上审议通 过。议案1-8对持股5%以下的股东的表决情况进行了单独计票。 本次股东大会相关议案审议通过后，公司第六届董事会组成如下： 董事：张强、王少君、王俊虹、韩瑛、张超、姜学进 三、律师见证情况 1、本次股东会见证的律师事务所：北京市两高律师事务所、北京市中视（济南）律师事务所 律师：张艳玲 魏本琳 杜加升 辛丽洁 2、律师见证结论意见： 北京市两高律师事务所张艳玲律师、魏本琳律师以及北京市中视（济南）律师事务所杜加升律师、辛丽 洁律师见证了本次股东会会议，并发表了法律意见。其意见为：本次股东会会议的召集和召开程序、召 集人和出席人员的资格、表决程序和表决结果符合《公司法》及《公司章程》的相关规定，合法、有 效。 特此公告。 艾格拉斯股份有限公司董事会 2025年12月19日 证券代码：400118 证券简称：R艾格1 主办券商：长城国瑞 公告编号：2025-001 艾格拉斯股份有限公司2025年第一次临时股东会决议公告 本公司董事会及全体董 ...

Group 1 - Changan Automobile received L3-level autonomous driving model product access permission from the Ministry of Industry and Information Technology, becoming one of the first models in China to obtain this qualification [2] - The company plans to conduct road trial applications with its partner, Changan Car Union Technology, in the first quarter of 2026, following the formal implementation of relevant national regulations and policies [2] - This week, Changan Automobile was the most researched company, with over 200 institutional inquiries, indicating strong interest in its L3 access situation [1][2] Group 2 - Over 600 companies have been researched by institutions since December, with nearly 170 companies disclosing institutional investor research records this week [1][3] - The top ten A-share listed companies by the number of institutional inquiries have been identified, with significant interest in sectors such as application software, electronic components, and automotive parts and equipment [1][3][5] - In the fourth quarter, nearly 2,500 listed companies have been researched by institutions, with Luxshare Precision, a leading electronic component company, receiving the highest number of inquiries at 600 [5][6]

Core Viewpoint - Beijing Tongrentang Group has issued an apology regarding the recent controversy surrounding "Antarctic Krill Oil," expressing deep concern for consumer rights and initiating a thorough investigation into the matter [1][3]. Group 1: Company Response - The company has launched a zero-tolerance brand management initiative and dispatched a special task force to Sichuan to conduct a comprehensive investigation into the involved products [3]. - The company has ordered the immediate removal of the implicated products from the market and is ensuring compliance with regulatory requirements for consumer compensation [3][4]. - Legal actions will be pursued against Sichuan Health and related e-commerce platforms for trademark infringement and misleading consumers [4]. Group 2: Product Investigation - The Shanghai Consumer Protection Committee has commissioned a study on 15 popular Antarctic krill oil products, focusing on their phospholipid, astaxanthin, EPA, and DHA content [5]. - A product labeled "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" was found to have a phospholipid content of 0%, despite claims of high quality and purity [5]. - The committee plans to interview the manufacturers and distributors of the product to clarify the discrepancies in product claims [5].

Core Viewpoint - China Shenhua plans to invest 133.598 billion yuan to acquire equity stakes in 11 core energy companies under the State Energy Group and 100% equity of Inner Mongolia Jian Investment held by Western Energy, with total asset scale exceeding 200 billion yuan [1][2]. Group 1: Business Expansion - The acquisition will significantly increase China Shenhua's business scale, with total assets expected to rise by over 200 billion yuan [2][3]. - Coal reserves will increase to 34.5 billion tons, a growth rate of 97.72%, while annual coal production will rise to 512 million tons, reflecting a growth rate of 56.57% [2]. - Power generation capacity will increase to 60.881 million kilowatts, a growth rate of 27.82%, and polyethylene production will rise to 1.88 million tons, with an increase of 213.33% [2]. Group 2: Industry Integration - The restructuring is a significant move for state-owned enterprises to address long-standing issues of intra-industry competition since 2004, enhancing resource reserves and core business capacity [3][4]. - The integration will optimize the entire industry chain, improving core competitiveness and supporting clean production and operational cost reduction [3][5]. Group 3: Policy Support - The restructuring is backed by favorable policies, including the simplified review process introduced by the China Securities Regulatory Commission, which will expedite the transaction [4]. - The new review process allows for a maximum of 12 working days from acceptance to approval, significantly enhancing transaction efficiency [4]. Group 4: Profitability Enhancement - The restructuring aims to create a full industry chain synergy, enhancing the company's quality and risk resistance, particularly during critical energy supply periods [5][6]. - China Shenhua has committed to a cash dividend policy, ensuring that the annual cash dividend ratio will not be less than 65% of the net profit attributable to shareholders [5][6]. Group 5: Market Impact - The restructuring is seen as a model for capital market service to the real economy and a benchmark for state-owned enterprise reform, potentially increasing market activity and scale [6]. - As of December 19, China Shenhua's stock price was 40.59 yuan per share, with a market capitalization of 790.9 billion yuan [7].

Meeting Information - The first extraordinary general meeting of Huishang Bank will be held on February 2, 2026, at 9:30 AM, expected to last half a day [1] - The meeting will be convened by the board of directors [2] - The location of the meeting is Huishang Bank Building, No. 1699 Yungu Road, Hefei, Anhui Province, China [3] - The meeting will be conducted in person with voting [4] Agenda Items - The meeting will review several proposals, including: 1. Proposal to abolish the supervisory board [5] 2. Proposal to amend the Articles of Association [5] 3. Proposal to amend the Rules of Procedure for Shareholders' Meetings [5] 4. Proposal to amend the Rules of Procedure for Board Meetings [5] - The first two proposals are special resolutions, while the last two are ordinary resolutions [6] Participation Details - Shareholders listed in the bank's register by the end of business on January 2, 2026, are eligible to attend [7] - Shareholders can appoint one or more proxies to attend and vote on their behalf [7] - Other attendees include directors, supervisors, senior management, and representatives from appointed intermediaries [8][9] Registration Information - Registration for the meeting will take place on February 1, 2026, from 9:30 AM to 12:00 PM and 2:00 PM to 5:30 PM [11] - The registration location is the board office on the 30th floor of Huishang Bank Building, No. 1699 Yungu Road, Hefei, Anhui Province [12] - Specific registration requirements are outlined for individual and corporate shareholders [13] Additional Information - Shareholders pledging more than 50% of their shares will have their voting rights limited [14] - The bank will suspend share transfer registration from January 3 to February 2, 2026, to determine eligible shareholders [14] - Contact information for inquiries is provided, including addresses and phone numbers [14]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 新奥天然气股份有限公司（以下简称"公司"）拟通过全资子公司私有化新奥能源控股有限公司（股票代 码：02688.HK，以下简称"新奥能源"），并同步以介绍上市方式在香港联合交易所有限公司（以下简 称"香港联交所"）主板上市（以下简称"本次介绍上市"），相关工作在持续推进中。 公司已于2025年6月16日向香港联交所递交了本次介绍上市的申请，并于同日在香港联交所网站刊登了 相关申请资料。 根据本次介绍上市的时间安排及香港联交所的相关规定，公司已于2025年12月17日向香港联交所更新递 交了本次介绍上市的申请，并于同日在香港联交所网站刊登了相关申请资料。该申请资料为公司按照香 港证券及期货事务监察委员会及香港联交所的要求编制和刊发，为草拟版本，可能会适时作出更新和修 订。 为使境内投资者及时了解该等申请资料披露的本次介绍上市以及公司的其他相关信息，现提供该申请资 料在香港联交所网站的查询链接供查阅： 公司将严格按照相关法律法规的规定和 ...

Core Viewpoint - The company has received approval from the U.S. FDA for its injectable bortezomib abbreviated new drug application (ANDA), indicating that the product is bioequivalent and therapeutically equivalent to the original drug, which enhances the company's international market presence and product pipeline [1][4]. Drug Basic Information - Drug Name: Injectable Bortezomib - Dosage Form: Injection - Specification: 3.5 mg - Approved Indications: - Treatment of multiple myeloma patients who have not received prior treatment and are not suitable for high-dose chemotherapy, in combination with melphalan and prednisone [1]. - Part of a combination therapy for multiple myeloma patients under 65 years old who have not received prior treatment, used for high-dose chemotherapy with autologous stem cell rescue following induction therapy [1]. - Treatment of multiple myeloma patients who have received at least one prior treatment and whose disease has progressed [2]. - Treatment of adult patients with mantle cell lymphoma who have not received prior treatment, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone [2]. Other Drug-Related Information - In April 2024, the product received a drug registration certificate from the National Medical Products Administration of China, indicating it passed the consistency evaluation [3]. - In October 2025, the product obtained marketing authorization from the Australian Therapeutic Goods Administration (TGA) [3]. Impact on the Company - The approval of the injectable bortezomib ANDA by the U.S. FDA signifies that the company's research and production meet original drug standards, showcasing its international research and production capabilities [4]. - This approval enriches the company's international sales product pipeline and advances its internationalization strategy, positively impacting the company's product influence and future operating performance [4]. - The approval grants the drug legal sales rights in the U.S., enhancing the company's market competitiveness and providing a new profit growth point for sustainable development [4].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1.本次股东会未出现否决提案的情形； 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、会议召开情况 1）会议召开时间：2025年12月18日14:45 2）会议召开地点：上海市浦东新区张杨路2389弄3号普洛斯大厦9楼公司会议室 3）会议召开方式：本次股东会采用现场表决与网络投票相结合的方式召开 网络投票时间为：2025年12月18日。其中，通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年12月18日的交易时间，即9:15一9:25，9:30一11:30和13:00一15:00；通过互联网投票系统进行网 络投票的具体时间为2025年12月18日9:15一15:00期间的任意时间。 4）股权登记日：2025年12月11日 5）会议召集人：公司董事会 6）会议主持人：公司董事长曾超林先生 7）本次股东会会议的召集、召开与表决程序符合《公司法》《上市公司股东会规则》《深圳证券交易 所上市公司股东会网络投票实施细则》 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或者重大 遗漏。 一、交易概述 贵州航天电器股份有限公司（以下简称"公司"）于2025年11月21日召开第八届董事会2025年第十二次临 时会议审议通过《关于拟以公开摘牌方式购买深圳市航天电机系统有限公司32%股权的议案》，董事会 同意公司使用自有资金以公开竞价摘牌方式参与航天科工深圳（集团）有限公司（以下简称"深圳科 工"）挂牌转让的深圳市航天电机系统有限公司（以下简称"航电系统"）32.00%股权（挂牌转让底价为 4,659.03万元），并授权公司董事长办理公开摘牌、签署相关合同等事宜。具体内容详见公司于2025年 11月22日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于拟以公开摘牌方式购买深圳市航天电 机系统有限公司32%股权的关联交易公告》（公告编号：2025-69）。 二、进展情况 根据公司第八届董事会2025年第十二次临时会议的批准与授权，公司向深圳联合产权交易所提交了深圳 科工所持航电系统32%股权的摘牌申请。近日，公司与深圳科工签订 ...

Core Viewpoint - The company has approved a share repurchase plan to utilize its own and raised funds for employee stock ownership plans or equity incentives, with a total repurchase amount between RMB 30 million and RMB 60 million, and a maximum repurchase price of RMB 6.5 per share [1][2]. Group 1: Share Repurchase Plan - The company plans to repurchase shares through centralized bidding, with a total amount not less than RMB 30 million and not exceeding RMB 60 million [1]. - The repurchase price will not exceed RMB 6.5 per share, which is 150% of the average trading price over the previous 30 trading days [1]. - The implementation period for the repurchase plan is set for 12 months from the board's approval date [1]. Group 2: First Share Repurchase Details - On December 17, 2025, the company repurchased 1,138,800 shares, accounting for 0.126% of the total share capital, at a maximum price of RMB 4.36 per share and a minimum price of RMB 4.27 per share, totaling RMB 4,913,960 (excluding transaction fees) [1]. - The funding for the repurchase comes from the company's own and raised funds, and the repurchase price did not exceed RMB 6.5 per share [2]. Group 3: Compliance and Regulations - The company has adhered to relevant regulations regarding the timing and method of share repurchase, ensuring no repurchase occurred during significant events that could impact stock prices [3]. - The repurchase was conducted in compliance with the requirements set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange [4]. - The company will continue to implement the repurchase plan based on market conditions and will fulfill its disclosure obligations as required by law [5].